Motley Fool. The Name Gives It's Defense For Less Than Truthfull Publishing.
Motley Fool Writers are failed authors that make a living by posting less that thorough scripted articles for The Street, Zack's and now SAC.
The newest article fails to disclose the real reason for owning Spectrum at $8.00 per share. There is no mention of the superior leadership that has put this company together by buying and licensing great oncology drugs from other companies that do not have the expertise or money to bring them to market. It does not mention Spectrum's ability to promote them with a well established, brilliant sales organization that has won the respect of the oncology specialist BECAUSE they knowledgeably sell effective products.
There is no mention of extensive patents, patent applications, and assigned patents that give Spectrum multiple opportunities to license and partner with major drug companies around the world. They fail to mention the years of profitable quarters, sales growth, positive cash flow, money in the bank and the potential to become a 1 billion dollar company if they were valued in the same manor as their peers. Peers that do not have the money and earnings that Spectrum has and many that are only "One Trick Pharma's" with phase 3 drugs.